Serum IL-6: a candidate biomarker for intracranial pressure elevation following isolated traumatic brain injury.
BACKGROUND: Increased intracranial pressure (ICP) is a serious, life-threatening, secondary event following traumatic brain injury (TBI). In many cases, ICP rises in a delayed fashion, reaching a maximal level 48-96 hours after the initial insult. While pressure catheters can be implanted to monitor ICP, there is no clinically proven method for determining a patient's risk for developing this pathology.
METHODS: In the present study, we employed antibody array and Luminex-based screening methods to interrogate the levels of inflammatory cytokines in the serum of healthy volunteers and in severe TBI patients (GCS
RESULTS: Consistent with previous reports, we observed sustained increases in IL-6 levels in TBI patients irrespective of their ICP status. However, the group of patients who subsequently experienced ICP >or= 25 mm Hg had significantly higher IL-6 levels within the first 17 hours of injury as compared to the patients whose ICP remained 128 pg/ml correctly identified 85% of isolated TBI patients who subsequently developed elevated ICP, and values between these cut-off values correctly identified 75% of all patients whose ICP remained
CONCLUSIONS: Our results suggest that serum IL-6 can be used for the differential diagnosis of elevated ICP in isolated TBI.
APACHE, Adolescent, Adult, Aged, Biological Markers, Brain Injuries, Cytokines, Enzyme-Linked Immunosorbent Assay, Female, Fractures, Bone, Glasgow Coma Scale, Humans, Injury Severity Score, Interleukin-6, Intracranial Hypertension, Male, Middle Aged, Multiple Trauma, Predictive Value of Tests, Prognosis, Reagent Kits, Diagnostic, Recruitment, Neurophysiological, Reproducibility of Results, Tomography, X-Ray Computed, Young Adult